Form D · Biotechnology
Exxel Pharma, INC.
Aurora, CO · CIK 0002046638
Offering snapshot reported Dec 2, 2024 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $125K Reported outside-investor minimum
- First sale
- Nov 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 2, 2024 | Initial | $600,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $60K
- Finders' fees
- $0
- Form D file number
- 021-530836
$675,000 Principal Amount of Debentures issued for $600,000
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Joseph Gunnar & Co, LLC | 24795 |
Source: Form D, filed Dec 2, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Soren Mogelsvang | Director, Executive |
| Guy Yachin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12635 East Montview Blvd Suite 134
Aurora, CO, 80045
Aurora, CO, 80045